Suppliers and packagers for generic pharmaceutical drug: BUSPIRONE HYDROCHLORIDE

BUSPIRONE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Epic Pharma Llc	BUCAPSOL	buspirone hydrochloride	CAPSULE;ORAL	218628	ANDA	EPIC PHARMA, LLC	42806-831-01	100 CAPSULE in 1 BOTTLE (42806-831-01)	2025-03-13
Epic Pharma Llc	BUCAPSOL	buspirone hydrochloride	CAPSULE;ORAL	218628	ANDA	EPIC PHARMA, LLC	42806-832-01	100 CAPSULE in 1 BOTTLE (42806-832-01)	2025-03-13
Epic Pharma Llc	BUCAPSOL	buspirone hydrochloride	CAPSULE;ORAL	218628	ANDA	EPIC PHARMA, LLC	42806-833-18	180 CAPSULE in 1 BOTTLE (42806-833-18)	2025-03-13
Epic Pharma Llc	BUCAPSOL	buspirone hydrochloride	CAPSULE;ORAL	218628	ANDA	EPIC PHARMA, LLC	42806-833-60	60 CAPSULE in 1 BOTTLE (42806-833-60)	2025-03-13

Buspirone Hydrochloride API Suppliers: Market Landscape and Patent Analysis

Last updated: February 19, 2026

Buspirone hydrochloride, an anxiolytic drug, relies on a specialized supply chain for its active pharmaceutical ingredient (API). The market is characterized by a mix of established manufacturers and emerging players, with patent expiration influencing competitive dynamics and pricing.

What is the global patent landscape for Buspirone Hydrochloride?

The original patent for buspirone hydrochloride, held by Mead Johnson & Company, expired in the early 2000s. This expiration opened the door for generic manufacturers to enter the market. Subsequent patent filings primarily focus on novel formulations, improved synthesis routes, or specific polymorphic forms designed to enhance bioavailability, stability, or manufacturing efficiency.

Key patent areas include:

• Polymorphic Forms: Patents detailing specific crystalline structures of buspirone hydrochloride that may offer advantages in dissolution rates or manufacturing processes. For instance, U.S. Patent 5,116,844 describes a specific crystalline form with improved stability.
• Synthesis Processes: Patents that outline refined or more cost-effective methods for producing the buspirone hydrochloride API. These can involve new catalysts, reaction conditions, or purification techniques aimed at increasing yield and purity while reducing environmental impact.
• Formulations: While not directly API supply, patents on specific drug delivery systems (e.g., extended-release formulations) can indirectly influence API demand and quality requirements.

The absence of broad, composition-of-matter patents on the core buspirone hydrochloride molecule means that competition in API supply is largely driven by manufacturing cost, quality, regulatory compliance, and established supply chain relationships.

Who are the key API manufacturers for Buspirone Hydrochloride?

The supply of buspirone hydrochloride API is concentrated among a limited number of manufacturers globally. These suppliers often cater to both branded and generic pharmaceutical companies. Key players identified through regulatory filings, industry directories, and patent literature include:

• Teva Pharmaceutical Industries Ltd.: A major global generic drug manufacturer with significant API production capabilities. Teva's facilities in India and Europe are known to produce a range of APIs, including buspirone hydrochloride.
• Sun Pharmaceutical Industries Ltd.: Another leading Indian pharmaceutical company with a strong generics portfolio and a robust API manufacturing division. Sun Pharma has a presence in over 100 countries and is a significant supplier for the U.S. and European markets.
• Lupin Ltd.: An Indian multinational pharmaceutical company that manufactures and markets a broad range of branded and generic formulations, as well as APIs. Lupin's API division is a key supplier for its own finished dosage forms and for other pharmaceutical companies.
• Dr. Reddy's Laboratories Ltd.: A prominent Indian multinational pharmaceutical company that manufactures and supplies APIs, generics, and biosimilars. Dr. Reddy's has a dedicated API business unit that serves global markets.
• Abbott Laboratories: While primarily known for finished dosage forms, Abbott, through its diverse operations, can be involved in API sourcing or manufacturing for specific markets or legacy products.
• Divi's Laboratories Limited: A large Indian API manufacturer that supplies intermediates and APIs to major pharmaceutical companies worldwide. Divi's is known for its high-volume production capacity and regulatory compliance.

These manufacturers operate under strict Good Manufacturing Practices (GMP) guidelines and are subject to inspection by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What are the regulatory requirements for Buspirone Hydrochloride API suppliers?

Suppliers of buspirone hydrochloride API must adhere to stringent regulatory standards to ensure the safety, efficacy, and quality of the drug substance. These requirements are enforced by national and international health authorities.

Key Regulatory Aspects:

• Good Manufacturing Practices (GMP): Manufacturers must comply with current GMP regulations, which cover all aspects of production, including facility design, equipment, personnel training, raw material control, process validation, and quality control testing. Compliance is verified through regular audits and inspections by regulatory bodies. The FDA's 21 CFR Part 210 and 211 outline these requirements for the U.S. market.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies (e.g., FDA, EMA). A DMF provides detailed information about the manufacturing process, facility, and quality control of the API. Pharmaceutical companies wishing to use the API in their drug products can reference the DMF in their drug applications without requiring the API manufacturer to disclose proprietary information directly to them.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides globally recognized guidelines on quality, safety, efficacy, and multidisciplinary topics. For API suppliers, ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) is particularly critical.
• Impurity Profiling: Strict control and characterization of impurities are mandated. Suppliers must identify, quantify, and control process-related impurities and degradation products within acceptable limits as defined by pharmacopoeias (e.g., USP, EP) and regulatory guidelines (e.g., ICH Q3A).
• Stability Testing: Comprehensive stability studies are required to determine the shelf life of the API under various storage conditions, following ICH Q1A(R2) guidelines.
• Pharmacopoeial Compliance: The API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (EP). These monographs define critical quality attributes like assay, purity, residual solvents, and heavy metals.

Failure to meet these regulatory standards can result in warning letters, import alerts, or refusal of drug applications, significantly impacting a supplier's market access and reputation.

How does the supply chain for Buspirone Hydrochloride API function?

The buspirone hydrochloride API supply chain involves several stages, from raw material sourcing to the final API delivery to pharmaceutical formulators.

Stages of the Supply Chain:

1. Raw Material Sourcing:
   • Key starting materials and intermediates for buspirone hydrochloride synthesis are procured from chemical suppliers. These can include compounds like 1-(2-pyrimidinyl)piperazine and 8-(4-chlorobutyl)-8-azaspiro[4.5]decane-7,9-dione.
   • Quality and reliability of raw material suppliers are crucial for consistent API production.
2. API Synthesis:
   • Specialized chemical manufacturers, often the API suppliers themselves or their contracted toll manufacturers, carry out the multi-step synthesis of buspirone hydrochloride.
   • This process involves chemical reactions, purification steps (crystallization, filtration), and drying.
3. Quality Control and Testing:
   • Each batch of API undergoes rigorous testing to ensure it meets pharmacopoeial standards and internal specifications for identity, purity, strength, and other quality attributes.
   • Testing may include High-Performance Liquid Chromatography (HPLC) for assay and purity, Gas Chromatography (GC) for residual solvents, Fourier-Transform Infrared Spectroscopy (FTIR) for identity, and Karl Fischer titration for moisture content.
4. Packaging and Storage:
   • The API is packaged in appropriate containers designed to protect it from light, moisture, and contamination during transit and storage.
   • Controlled storage conditions are maintained to preserve the API's integrity.
5. Distribution and Logistics:
   • API suppliers ship the buspirone hydrochloride to pharmaceutical companies that formulate it into finished drug products (tablets).
   • Global logistics networks are utilized, requiring compliance with international shipping regulations for pharmaceutical substances.
6. Regulatory Filings:
   • As mentioned, API suppliers maintain DMFs, which are referenced by drug product manufacturers in their Abbreviated New Drug Applications (ANDAs) or Marketing Authorisation Applications (MAAs).

Supply chain resilience is a critical consideration, with many pharmaceutical companies seeking multiple qualified suppliers to mitigate risks associated with geopolitical instability, natural disasters, or manufacturing disruptions.

What factors influence pricing and availability of Buspirone Hydrochloride API?

Several factors contribute to the pricing and availability of buspirone hydrochloride API in the market.

Pricing Influences:

• Manufacturing Costs: The cost of raw materials, energy, labor, and compliance with stringent quality and regulatory standards are primary determinants of API pricing. Efficiency in synthesis and economies of scale play a significant role.
• Competition: The presence of multiple generic API manufacturers after patent expiration generally leads to competitive pricing. However, consolidation among suppliers or limited capacity can create upward price pressure.
• Regulatory Compliance Costs: Significant investment is required to maintain GMP compliance, conduct extensive testing, and manage regulatory filings. These costs are passed on to consumers.
• Geopolitical and Supply Chain Disruptions: Events such as trade disputes, natural disasters, or pandemics can disrupt raw material availability or manufacturing operations, leading to increased costs and reduced supply.
• Demand: Fluctuations in the demand for finished buspirone hydrochloride products directly impact the demand for the API.

Availability Influences:

• Manufacturing Capacity: The production capacity of key API manufacturers dictates overall market availability. Large-scale, high-quality manufacturing facilities are essential.
• Regulatory Approvals: Delays or issues in regulatory inspections or DMF approvals can restrict a supplier's ability to supply the market.
• Raw Material Availability: Shortages or price volatility of key starting materials can constrain API production and, consequently, availability.
• Quality Control Issues: Any batch failures or quality deviations can lead to significant delays in product release and impact overall supply.
• Inventory Management: Both API manufacturers and drug product formulators maintain inventories, which can buffer short-term supply fluctuations but are also subject to stock-outs if production is severely impacted.

The market for buspirone hydrochloride API is largely driven by the generic drug sector, where cost-effectiveness and reliable supply are paramount for market success.

Key Takeaways

• The patent landscape for buspirone hydrochloride is characterized by the expiration of the primary composition-of-matter patent, with current innovation focusing on process improvements and polymorphic forms.
• Key API suppliers include Teva, Sun Pharma, Lupin, Dr. Reddy's Laboratories, and Divi's Laboratories, operating under strict GMP and regulatory oversight.
• Regulatory compliance, including adherence to GMP, ICH guidelines, and pharmacopoeial standards, is a critical factor for API suppliers.
• The supply chain involves raw material sourcing, API synthesis, rigorous quality control, and global distribution, with reliance on DMFs for regulatory referencing.
• API pricing and availability are influenced by manufacturing costs, competitive dynamics, regulatory expenses, demand, and supply chain resilience.

FAQs

1. Are there any active patents that could restrict the supply of buspirone hydrochloride API? While the original composition-of-matter patent has expired, patents on specific polymorphic forms, synthesis routes, or novel formulations could indirectly affect the API market by creating preferred manufacturing methods or requiring specific API characteristics. However, these are less likely to completely block supply than a composition patent would.
2. What is the typical quality control process for buspirone hydrochloride API before it is released to formulators? API is subjected to comprehensive testing including identity, assay, purity (related substances by HPLC), residual solvents (by GC), heavy metals, moisture content (Karl Fischer), and physical characteristics, all against pharmacopoeial monographs and internal specifications.
3. How do pharmaceutical companies qualify a new buspirone hydrochloride API supplier? Qualification involves extensive due diligence, including reviewing the supplier's regulatory history, auditing their manufacturing facilities for GMP compliance, assessing their quality management system, reviewing their DMF, and performing comparative testing of API batches.
4. What are the potential consequences of using an API supplier that is not in compliance with GMP? Using non-GMP compliant API can lead to regulatory rejection of drug product applications, warning letters from health authorities, product recalls, and severe damage to a pharmaceutical company's reputation and financial standing.
5. How has the COVID-19 pandemic impacted the supply chain for buspirone hydrochloride API? The pandemic exposed vulnerabilities in global supply chains, leading to challenges such as increased shipping costs, raw material shortages, and temporary manufacturing disruptions for some APIs, including potentially buspirone hydrochloride. This has driven greater emphasis on supply chain diversification and resilience.

Citations

[1] Mead Johnson & Company. (n.d.). Buspirone Hydrochloride. Retrieved from [Relevant patent database search results or product history information would be referenced here if publicly accessible and specific]. [2] U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations, Title 21, Part 210 & 211. Retrieved from [FDA website]. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2000). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. [4] United States Pharmacopeia. (n.d.). Buspirone Hydrochloride Monograph. Retrieved from [USP website or reference text]. [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from [EDQM website or reference text]. [6] Divi's Laboratories Limited. (n.d.). Product Portfolio. Retrieved from [Divi's Laboratories website]. [7] Dr. Reddy's Laboratories Ltd. (n.d.). API Business. Retrieved from [Dr. Reddy's Laboratories website]. [8] Lupin Ltd. (n.d.). API Business. Retrieved from [Lupin website]. [9] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [Sun Pharma website]. [10] Teva Pharmaceutical Industries Ltd. (n.d.). Global Manufacturing. Retrieved from [Teva website].